Compare BHB & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHB | ZVRA |
|---|---|---|
| Founded | 1887 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.2M | 741.9M |
| IPO Year | 1995 | 2015 |
| Metric | BHB | ZVRA |
|---|---|---|
| Price | $37.66 | $13.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $37.00 | $23.00 |
| AVG Volume (30 Days) | 149.7K | ★ 1.8M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.95% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | ★ 0.81 | 0.60 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $22.68 | $37.27 |
| Revenue Next Year | $3.66 | $53.42 |
| P/E Ratio | $46.49 | ★ $23.30 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $28.06 | $7.16 |
| 52 Week High | $39.67 | $14.58 |
| Indicator | BHB | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.09 | 64.82 |
| Support Level | $33.85 | $8.26 |
| Resistance Level | N/A | $14.27 |
| Average True Range (ATR) | 1.05 | 0.60 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 49.87 | 75.00 |
Bar Harbor Bankshares Inc is a bank holding company along with its subsidiaries that offers a full range of financial services products, brokerage services through third-party brokerage arrangements, and also trust and investment management services to individuals, businesses, non-profit organizations, and municipalities. Its products and services consist of checking, deposits, cards, mobile banking, online services, loans, merchant services, trust, fiduciary services, investment planning, education funding, and individual retirement planning.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.